NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry
Authors
Keywords
-
Journal
MOLECULES
Volume 24, Issue 10, Pages 1995
Publisher
MDPI AG
Online
2019-05-24
DOI
10.3390/molecules24101995
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
- (2019) Reece G. Kenny et al. CHEMICAL REVIEWS
- Structure–activity relationships for ruthenium and osmium anticancer agents – towards clinical development
- (2018) Samuel M. Meier-Menches et al. CHEMICAL SOCIETY REVIEWS
- The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions
- (2018) Alberta Bergamo et al. COORDINATION CHEMISTRY REVIEWS
- Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents
- (2018) Mousumi Pal et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNA Phe
- (2018) Brendan G. Dwyer et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
- (2018) Sreekanth Thota et al. JOURNAL OF MEDICINAL CHEMISTRY
- Ruthenium coordination compounds of biological and biomedical significance. DNA binding agents
- (2018) Viktor Brabec et al. COORDINATION CHEMISTRY REVIEWS
- The NAMI A – human ferritin system: a biophysical characterization
- (2018) Silvia Ciambellotti et al. DALTON TRANSACTIONS
- Metal Drugs and the Anticancer Immune Response
- (2018) Bernhard Englinger et al. CHEMICAL REVIEWS
- A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress
- (2017) Peter M Bruno et al. NATURE MEDICINE
- A systematic assessment of chemical, genetic, and epigenetic factors influencing the activity of anticancer drug KP1019 (FFC14A)
- (2017) Upendarrao Golla et al. Oncotarget
- Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse
- (2017) Amir Blazevic et al. Scientific Reports
- Interactions between proteins and Ru compounds of medicinal interest: A structural perspective
- (2016) Antonello Merlino COORDINATION CHEMISTRY REVIEWS
- Thirty Years of the Drug Candidate NAMI-A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective
- (2016) Enzo Alessio EUROPEAN JOURNAL OF INORGANIC CHEMISTRY
- RuIIIComplexes for Anticancer Therapy: The Importance of Being Nucleolipidic
- (2016) Claudia Riccardi et al. EUROPEAN JOURNAL OF ORGANIC CHEMISTRY
- Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines
- (2016) Lea S. Flocke et al. INVESTIGATIONAL NEW DRUGS
- Biodistribution of the novel anticancer drug sodium trans -[tetrachloridobis(1 H -indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action
- (2016) Anna K. Bytzek et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A
- (2016) Chiara Pelillo et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism
- (2016) Aleksandar Bijelic et al. JOURNAL OF MEDICINAL CHEMISTRY
- Comparison of KP1019 and NAMI-A in tumour-mimetic environments
- (2016) Gemma K. Gransbury et al. Metallomics
- Linking the future of anticancer metal-complexes to the therapy of tumour metastases
- (2015) Alberta Bergamo et al. CHEMICAL SOCIETY REVIEWS
- Noble metals in medicine: Latest advances
- (2015) Serenella Medici et al. COORDINATION CHEMISTRY REVIEWS
- Albumin binding and ligand-exchange processes of the Ru(iii) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy
- (2015) Michael I. Webb et al. DALTON TRANSACTIONS
- Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity
- (2015) V. Novohradský et al. DALTON TRANSACTIONS
- Interaction of anticancer Ru(iii) complexes with single stranded and duplex DNA model systems
- (2015) Domenica Musumeci et al. DALTON TRANSACTIONS
- Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs
- (2015) Ekaterina Schreiber-Brynzak et al. INVESTIGATIONAL NEW DRUGS
- Impact of low- and high-molecular-mass components of human serum on NAMI-A binding to transferrin
- (2015) K. Śpiewak et al. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
- NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels
- (2014) Serena Pillozzi et al. DALTON TRANSACTIONS
- Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
- (2014) Suzanne Leijen et al. INVESTIGATIONAL NEW DRUGS
- NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
- (2014) Robert Trondl et al. Chemical Science
- Biotransformations of Anticancer Ruthenium(III) Complexes: An X-Ray Absorption Spectroscopic Study
- (2013) Aviva Levina et al. CHEMISTRY-A EUROPEAN JOURNAL
- Interaction of Anticancer Ruthenium Compounds with Proteins: High-Resolution X-ray Structures and Raman Microscopy Studies of the Adduct between Hen Egg White Lysozyme and AziRu
- (2013) Alessandro Vergara et al. INORGANIC CHEMISTRY
- EPR as a probe of the intracellular speciation of ruthenium(iii) anticancer compounds
- (2013) Michael I. Webb et al. Metallomics
- Structure and dynamics of drug carriers and their interaction with cellular receptors: Focus on serum transferrin
- (2012) Ashley N. Luck et al. ADVANCED DRUG DELIVERY REVIEWS
- Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies
- (2012) Orsolya Dömötör et al. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
- Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells
- (2012) Jade B. Aitken et al. Metallomics
- The transferrin receptor and the targeted delivery of therapeutic agents against cancer
- (2011) Tracy R. Daniels et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(iii) complex NAMI-A by interactions with human serum albumin
- (2011) Michael I. Webb et al. DALTON TRANSACTIONS
- Metal-based antitumour drugs in the post-genomic era: what comes next?
- (2011) Gianni Sava et al. DALTON TRANSACTIONS
- Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors
- (2011) M.M. Henke et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro
- (2011) Alethia A. Hostetter et al. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
- Approaching tumour therapy beyond platinum drugs
- (2011) A. Bergamo et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- Characterization of a Ruthenium(III)/NAMI-A Adduct with Bovine Serum Albumin that Exhibits a High Anti-Metastatic Activity
- (2010) Mimi Liu et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Ruthenium-based chemotherapeutics: are they ready for prime time?
- (2010) Emmanuel S. Antonarakis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The X-ray Structure of the Adduct between NAMI-A and Carbonic Anhydrase Provides Insights into the Reactivity of this Metallodrug with Proteins
- (2010) Angela Casini et al. ChemMedChem
- Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339
- (2010) Petra Heffeter et al. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
- Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry
- (2010) Michael Groessl et al. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
- Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR
- (2009) Naniye Cetinbas et al. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
- Recent developments in ruthenium anticancer drugs
- (2009) Aviva Levina et al. Metallomics
- KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
- (2008) Christian G. Hartinger et al. CHEMISTRY & BIODIVERSITY
- Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: A novel approach for the analysis of anticancer metallodrugs in human serum and plasma
- (2008) Michael Groessl et al. ELECTROPHORESIS
- Synthesis and Reactivity of the Aquation Product of the Antitumor Complextrans-[RuIIICl4(indazole)2]−
- (2008) Berta Cebrián-Losantos et al. INORGANIC CHEMISTRY
- Antitumour metal compounds: more than theme and variations
- (2007) Michael A. Jakupec et al. DALTON TRANSACTIONS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now